BIIB vs RAL · P/E 21, rev $9.89B vs rev $2.07B
Biogen Inc (BIIB) versus Ralliant Corporation Common Stock (RAL) — a side-by-side from cached financials, not a winner call.
Biogen Inc (BIIB) is a drug manufacturers - general company listed on NASDAQ.
Ralliant Corporation Common Stock (RAL) is a electronic components company listed on NYSE.
Latest reported BIIB revenue for 2025-12-31 was $9.89B. Net income was $1.29B. Revenue was up 2.2% from 2024-12-31 to 2025-12-31. BIIB currently screens at market cap $29.33B and trailing P/E 21.4.
Latest reported RAL revenue for 2025-12-31 was $2.07B. Net income was -$1.22B. Revenue was down 4.0% from 2024-12-31 to 2025-12-31. RAL currently screens at market cap $7.76B.
BIIB currently screens at market cap $29.33B and trailing P/E 21.4. RAL currently screens at market cap $7.76B.
Not investment advice. Open the BIIB and RAL stock pages for the full models.
Not investment advice.